Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
Tóm tắt
This meta-analysis was performed to determine the optimal use of anti-EGFR mAb in the treatment of metastasized colorectal cancer (mCRC). Seventeen randomized clinical trials were included, all evaluating the added value of anti-EGFR mAb to standard treatment line in patients with KRAS wild-type mCRC. Hazard and odds ratios were pooled using a random effect model, weighted according to cohort size. Pooled data of six first- and two second-line studies demonstrated a significantly improved ORR (OR 1.62, CI 1.27–2.04; OR 4.78, CI 3.39–6.75, respectively) and PFS (HR 0.79, CI 0.67–0.94; HR 0.80, CI 0.71–0.91, respectively) with the addition of anti-EGFR mAb to chemotherapy, while OS remained similar. Two third-line anti-EGFR mAb monotherapy studies revealed an improved PFS and OS (HR 0.44, CI 0.35–0.52; HR 0.55, CI 0.41–0.74). Addition of anti-EGFR versus anti-VEGF mAb to first-line chemotherapy was evaluated in three studies; ORR and PFS were comparable, while OS was improved (HR 0.8, CI 0.65–0.97). The influence of the chemotherapy backbone on anti-EGFR mAb efficacy, evaluated with meta-regression, indicated a higher ORR with irinotecan-based versus oxaliplatin-based regimens, but comparable PFS and OS. Reported toxicity (≥3 grade) increased ~20% in all treatment lines with the addition of anti-EGFR mAb. Anti-EGFR treatment significantly improves response and survival outcome of patients with (K)RAS wild-type mCRC, regardless of treatment line or chemotherapeutic backbone. Saving anti-EGFR mAb as third-line monotherapy is a valid and effective option to prevent high treatment burden caused by combination therapy. Combination treatment with anti-EGFR mAb to achieve radical resection of metastases needs further investigation.
Tài liệu tham khảo
Cosmai, L., Gallieni, M., & Porta, C. (2015). Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of Nephrology, 28(6), 647–657.
Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Mahoney MR, O'Neil BH, et al. (2014). CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (MFOLFOX6) with bevacizumab (bv) or cetuximab (CET) for patients (PTS) with kras wild-type (WT) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Journal of Clinical Oncology. 32(18).
Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008). The biological properties of cetuximab. Critical Reviews in Oncology/Hematology, 68(2), 93–106.
Amado, R. G., Wolf, M., Peeters, M., Van, C. E., Siena, S., Freeman, D. J., et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(10), 1626–1634.
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine, 359(17), 1757–1765.
Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et al. (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England Journal of Medicine, 369(11), 1023–1034.
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., et al. (2014). Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology, 15(6), 569–579.
Folprecht, G., Gruenberger, T., Bechstein, W., Raab, H. R., Weitz, J., Lordick, F., et al. (2013). Survival of patients with initially non-resectable colorectal liver metastases following systemic treatment with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). Onkologie, 36, 70.
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de BF, Schuch, G., Zubel, A., et al. (2011). Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology, 22(7), 1535–1546.
Cutsem, E., Köhne, C. H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., et al. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology, 29(15), 2011–2019.
Tveit, K. M., Guren, T., Glimelius, B., Pfeiffer, P., Sorbye, H., Pyrhonen, S., et al. (2012). Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Journal of Clinical Oncology, 30(15), 1755–1762.
Ye, L. C., Liu, T. S., Ren, L., Wei, Y., Zhu, D. X., Zai, S. Y., et al. (2013). Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. Journal of Clinical Oncology, 31(16), 1931–1938.
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., et al. (2011). Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, 377(9783), 2103–2114.
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. (2014). Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(7), 1346–1355.
Bokemeyer, C., Kohne, C-H., Ciardiello, F., Lenz, H-J., Heinemann, V., Klinkhardt, U., et al. (2014). Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. Journal of Clinical Oncology. 32(15).
Cutsem, E., Lenz, H. J., Köhne, C. H., Heinemann, V., Tejpar, S., Melezínek, I., et al. (2015). Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 33, 692–700.
Douillard, J-Y., Siena, S., Tabernero, J., Burkes, R. L., Barugel, M. E., Humblet, Y., et al. (2013). Overall survival (OS) analysis from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 31(15).
Seymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., et al. (2013). Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14(8), 749–759.
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2014). Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(1), 107–116.
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et al. (2015). Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clinical Cancer Research., 21(24), 5469–5479.
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J. L., Hecht, J. R., et al. (2014). PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Journal of Clinical Oncology, 32(21), 2240–2247.
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S. E., et al. (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology.
Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., et al. (2014). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. The Lancet Oncology, 15(6), 601–611.
Basso, M., Dadduzio, V., Ardito, F., Lombardi, P., Strippoli, A., Vellone, M., et al. (2016). Conversion chemotherapy for technically unresectable colorectal liver metastases: a retrospective, STROBE-compliant, single-center study comparing chemotherapy alone and combination chemotherapy with cetuximab or bevacizumab. Medicine (Baltimore), 95(20), e3722.
Huiskens, J., van Gulik, T. M., van Lienden, K. P., Engelbrecht, M. R., Meijer, G. A., van Grieken, N. C., et al. (2015). Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer, 15, 365.
Chan, D. L., Pavlakis, N., Shapiro, J., Price, T. J., Karapetis, C. S., Tebbutt, N. C., et al. (2015). Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature. PloS One, 10(8), e0135599.
Zhou, S. W., Huang, Y. Y., Wei, Y., Jiang, Z. M., Zhang, Y. D., Yang, Q., et al. (2012). No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PloS One, 7(11), e50925.
Ocvirk, J., Brodowicz, T., Wrba, F., Ciuleanu, T. E., Kurteva, G., Beslija, S., et al. (2010). Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World Journal of Gastroenterology : WJG, 16(25), 3133–3143.
Cheng, A. L., Cornelio, G., Shen, L., Price, T., Yang, T. S., Chung, I. J., et al. (2013). First-line cetuximab with folfox or FOLFIRI every 2 weeks in KRAS wild-type metastatic colorectal cancer: phase II APEC study. Annals of Oncology, 24, iv34–iiv5.
Moosmann, N., Weikersthal, L. F., Vehling-Kaiser, U., Stauch, M., Hass, H. G., Dietzfelbinger, H., et al. (2011). Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. Journal of Clinical Oncology, 29(8), 1050–1058.
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., et al. (2016). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. The Lancet Oncology, 17(10), 1426–1434.
Modest, D.P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. (1527–7755 (Electronic)).
Hecht, J. R., Cohn, A., Dakhil, S., Saleh, M., Piperdi, B., Cline, B. M., et al. (2015). SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clinical Colorectal Cancer, 14, 72–80.
Grothey, A. (2016). RAS wild-type patients should receive anti-VEGF therapy in first line. Presented at the ASCO Annual Meeting: June 2016; Chicago, IL.
Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F. L., et al. (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 370(9582), 135–142.
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., et al. (2007). Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 370(9582), 143–152.
Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., et al. (2009). Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology, 20(2), 244–250.
Ducreux, M., Malka, D., Mendiboure, J., Etienne, P. L., Texereau, P., Auby, D., et al. (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. The Lancet Oncology, 12(11), 1032–1044.
Seymour, M. T., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., et al. (2011). Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, 377(9779), 1749–1759.
Asmis, T., Berry, S., Cosby, R., Chan, K., Coburn, N., & Rother, M. (2014). Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Current Oncology, 21(6), 318–328.
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., et al. (2016). High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer. International Journal Molecular Science. 17(12).
Diaz Jr., L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., et al. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 486(7404), 537–540.
Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A. M., et al. (2013). Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clinical Chemistry, 59(1), 252–260.
Schrag, D.. (2016). The relationship between primary tumor sidedness and prognosis in colorectal cancer. Presented at the ASCO Annual Meeting, abstract no 3505, June 2016; Chicago, IL.
Arnold, D., Lueza, B., Douillard, J. Y., Peeters, M., Lenz, H. J., Venook, A., et al. (2017). Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Annals Oncology.